Singapore, Feb. 19 -- Hummingbird Bioscience, a systems-biology enabled biotech company focused on the discovery and development of cancer therapeutics has announced that James P. Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D., have joined its Scientific Advisory Board.

Dr. Allison has spent his career studying the regulation of T cell responses. In 2018, he shared the Nobel Prize in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation. Dr. Allison's work led to the development of an antibody to human CTLA-4 called ipilimumab which became the first immune checkpoint blockade therapy ever approved by the U.S. Food and Drug Administration (FDA).

The approval of ipilimumab cleared the path...